Description
Binimetinib
Each film-coated tablet contains: Binimetinib … 15mg.
INDICATION
LuciBinim is a kinase inhibitor indicated, in combination with Encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
DOSAGE AND USE
• Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to the initiation of LuciBinim. • The recommended dose is 45 mg orally twice daily in combination with Encorafenib. Take LuciBinim with or without food. • For patients with moderate or severe hepatic impairment the recommended dose is 30 mg orally twice daily.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciBinim during Pregnancy and Lactation.
Reviews
There are no reviews yet.